The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: Final results of a 5-year, double-blind, levodopa-controlled study

CNS Drugs

Volumn 18, Issue 11, 2004, Pages 733-746

  Bracco, Fulvio ^a   Battaglia, Angelo ^b   Chouza, Carlos ^c   Dupont, Erik ^d   Gershanik, Oscar ^e   Masso, Jose Felix Marti ^f   Montastruc, Jean Louis ^g  

^a UNIVERSITY OF PADOVA   (Italy)

^b PFIZER INC   (United States)

^c HOSPITAL DE CLÍNICAS   (Uruguay)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e HOSPITAL FRANCÉS   (Argentina)

^f Hospital Nuestra Senora de Aranzazu   (Spain)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LONG ACTING DRUG;

ADD ON THERAPY; ADULT; AGED; AGITATION; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DYSKINESIA; DYSPEPSIA; FEMALE; GASTRITIS; HALLUCINATION; HEADACHE; HUMAN; HYPERKINESIA; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MONOTHERAPY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RISK ASSESSMENT; SEX DIFFERENCE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; VOMITING;

ADULT; AGED; ANTIPARKINSON AGENTS; CASE-CONTROL STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; ERGOLINES; FEMALE; HUMANS; LEVODOPA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOTOR ACTIVITY; MOVEMENT DISORDERS; PARKINSON DISEASE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 4544226873     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418110-00003     Document Type: Article

References (21)

1. Jankovic J. Levodopa strengths and weaknesses. Neurology 2002; 58: S19-32
2. Rinne UK. Recent advances in research on parkinsonism. Acta Neurol Scand 1978; 57: 77-113
3. Bravi D, Mouradian MM, Roberts JW, et al. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994; 36: 27-31
4. Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986; 49: 853-60
5. Rodriguez M, Lera G, Vaamonde J, et al. Motor response to apomorphine and levodopa in asymmetric Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 562-6
6. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995; 18: 338-47
7. Tanner CM. Dopamine agonists in early therapy for Parkinson disease. JAMA 2000; 284: 1971-3
8. Montastruc JL, Rascol O, Senard JM, et al. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994; 57: 1034-8
9. Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 1997; 48: 363-8
10. Wiseman LR, Fitton A. Cabergoline: a review of its efficacy in the treatment of Parkinson's disease. CNS Drugs 1999; 12: 485-97
11. Barone P, Bravi D, Bermejo-Pareja F, et al. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Neurology 1999; 53: 573-9
12. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease. JAMA 2000; 284: 1931-8
13. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342: 1484-91
14. Rascol O. Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease? J Neural Transm Suppl 1999; 55: 33-45
15. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications: results of a double-blind levodopa controlled trial. Drugs 1998; 55 Suppl. 1: 20-3
16. Marubini E, Valsecchi MG. Analyzing survival data from clinical trials and observational studies. New York: John Wiley & Sons, 1995
17. Everitt BS. The analysis of repeated measures: a practical review with examples. Statistician 1995; 44: 113-35
18. Block G, Liss C, Reines S, et al. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease: a multicenter 5-year study. The CR First Study Group. Eur Neurol 1997; 37: 23-7
19. Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002; 58: 11-7
20. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003; 60 (3): 381-9
21. Albin RL, Frey KA. Initial agonist treatment of Parkinson disease: a critique. Neurology 2003; 60 (3): 390-4